Prostate cancer is the most prevalent non-skin cancer in men and is the leading cause of
cancer-related death. Early detection of prostate cancer is largely determined by a widely …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …

Prostate cancer is notoriously difficult to treat, which makes its early detection a priority.
Biomarkers have been used to diagnose and monitor prostate cancer for more than 50 …

Since the introduction of serum prostate-specific antigen (PSA) screening 25 years ago,
prostate cancer diagnosis and management have been guided by this biomarker. Yet, PSA …

Although prostate-specific antigen (PSA) has evolved as a very useful tool for detection of
prostate cancer, there remains an urgent need for more accurate biomarkers to diagnose …

Biomarkers are important for early detection of cancer, prognosis, response prediction, and
detection of residual or relapsing disease. Special attention has been given to diagnostic …

Carcinoma of the prostate is the second leading cause of male cancer-related death in the
United States. Better indicators of prostate cancer presence and progression are needed to …

Only 30% of patients with elevated serum prostate specific antigen (PSA) levels who
undergo prostate biopsy are diagnosed with prostate cancer (PCa). Novel methods are …

Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the
leading causes of cancer-related death worldwide. It is a highly heterogeneous disease …

In recent years the discovery of cancer biomarkers has become a major focus of cancer
research. The widespread use of prostate-specific antigen in prostate cancer screening has …